VBLT - VBL Therapeutics' stock up on late-stage VB-111 ovarian cancer study results

VBL Therapeutics (VBLT) shares jump 7% premarket after announcing the online publication of positive results of the pre-specified interim analysis of the OVAL study, a Phase 3 registration enabling study of VB-111 (ofranergene obadenovec) in recurrent platinum-resistant ovarian cancer.The analysis showed a CA-125 GCIG response rate of 58% or higher in evaluable patients in the VB-111 treatment arm.Based on the results of the interim analysis, the Data and Safety Monitoring Committee ((DSMC)) recommended continuing the trial as planned.OVAL is an international Phase 3 randomized pivotal registration enabling clinical trial that compares a combination of VB-111 and paclitaxel to placebo plus paclitaxel, in patients with platinum-resistant ovarian cancer. The study is planned to enroll about 400 patients.

For further details see:

VBL Therapeutics' stock up on late-stage VB-111 ovarian cancer study results